All Blogs / Industries / Medical / Pharmaceutical / Popular

New Directions for FDA, Part 2 – Regulatory Matters

In Part 1 about change facing FDA, we looked at the 21st Century Cures Act and some of the change that would be in store for FDA. But in this post-election cycle, there is more than pending legislation that could … Continue reading ...

Can This Work for Pharma? The Continual Quest of Creative Advertisers

PM360 magazine is asking its readers find marketing campaigns and tactics used by consumer packaged goods, retail, and other industries to give pharma marketers some fresh ideas. Here's what one ad agency SVP Executive Creative Director...Show More Summary

FDA Compliant Diclegis Instagram Promo by (Good) Emily Maynard Johnson Can't Compete with (Bad) Kim Kardashian's Violative Post

About 22 weeks ago, Emily Maynard Johnson, who appeared on ABC's The Bachelor and The Bachelorette, posted the following Diclegis promotion to her Instagram account: I assume you've noticed that all the ISI (Important Safety Information)...Show More Summary

CVS Changes Direction With Surprise OptumRx Deal

Well, CVS Health blinked. In July 2017, CVS Health’s retail pharmacies will become a preferred retail channel for 90-day prescriptions dispensed to OptumRx’s commercial clients. Here’s the press release: OptumRx and CVS Pharmacy Partner...Show More Summary

New Directions for FDA, Part 1 – 21st Century Cures

One of the often stated priorities for lame-duck Congress has been voting on the 21st Century Cures Act. In a press release from Saturday, November 26 from the House Energy and Commerce Committee, the House is set to vote on … Continue reading ?

Drug Channels News Roundup, November 2016: CVS Caremark, Generic Drugs, Health-System Pharmacies, and the FDA

Hope everyone enjoyed the Thanksgiving holiday! Now that you’ve stretched your stomach, stretch your mind with some food for thought. In this issue: Dispensing oncology practices win their battle with PBM CVS Caremark 2016 was a record...Show More Summary

Expanded Access Programs 2017

Expanded Access Programs 2017March 9-10, 2017 | Washington, DCThe evolving political landscape is transforming and expanding patient access to experimental and unapproved drugs. CBI’s Expanded Access Programs is dedicated to the nuances and intricacies of designing and implementing early access programs. Show More Summary

CBI’s 12th Life Sciences Trade and Channel Strategies

CBI’s 12th Life Sciences Trade and Channel StrategiesDecember 13-14, 2016 | Philadelphia,’t miss the must-attend event for industry trade, channel, account and pharmacy strategy professionals!CBI’s Annual Trade...Show More Summary

UN World Toilet Day 2016

PLOS Medicine and PLOS NTDs reflect on 15 years of World Toilet Day and announce the WASH Collection. UN World Toilet Day highlights the urgent need to address a global sanitation crisis by providing toilets

A Post-Election Projection: The 2025 Payer Market for Prescription Drugs

In Latest CMS Forecast Shows Big Drug Spending Growth Through 2025, I examined the July 2016 drug spending forecasts from the Centers for Medicare & Medicaid Services (CMS). Alas, last week’s election exploded these projections. Today, I analyze CMS’s official pre-election insights about payment for outpatient prescriptions drugs in 2025. Show More Summary

Vaccinations, Vaccine Science, and a New US President

PLOS NTDs co-Editor in Chief Peter Hotez encourages US President-Elect Donald Trump to support pro-vaccine policies to protect public health. The 2016 US Presidential debates and campaign were mostly devoid of any meaningful science policy discussions. Beyond climate

Genentech’s Shocking $2 Billion 340B Revelation

ICYMI, the Roche Group recently made a startling disclosure: For the first half of 2016, the 340B Drug Pricing Program accounted for 18% of Genentech’s volume. I estimate that at that rate, hospitals and other 340B-covered entities claimed discounts on about $3.4 billion in purchases annually from Genentech. Show More Summary

The Evolution of the Written Word in the Social Media Information Age

I started writing about the drug industry – specifically the commercial side of the industry – in 2002 with the publication of the first issue of Pharma Marketing News. At the dawn of the social media age in 2005, I started writing Pharma...Show More Summary

Specialty Therapies 2017

Specialty Therapies 2017January 26-27, 2017 | Las Vegas, NVHead to Las Vegas this January to share and learn strategies for managing the high cost of specialty therapies management. Through thought-provoking sessions, panels and keynotes,...Show More Summary

Catching up with the author: Gareth Whitely on snake venom and antivenom research

Venomous snakes are widely dispersed across the globe, occupying a range of habits in both terrestrial and marine environments. A major part of venomous snakes’ predatory success is the venom proteins, which cause rapid cardiovascul...

Copyright © 2015 Regator, LLC